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Extracellular chaperones modulate the effects of Alzheimer's patient
cerebrospinal fluid on A beta(1-42) toxicity and uptake
Abstract
Alzheimer's disease is characterised by the inappropriate death of brain cells and accumulation of the A
beta peptide in the brain. Thus, it is possible that there are fundamental differences between Alzheimer's
disease patients and healthy individuals in their abilities to clear A beta from brain fluid and to protect
neurons from A beta toxicity. In the present study, we examined (1) the cytotoxicity of Alzheimer's disease
cerebrospinal fluid (CSF) compared to control CSF, (2) the ability of Alzheimer's disease and control CSF
to protect cells from A beta toxicity and to promote cell-mediated clearance of A beta and lastly (3) the
effects of extracellular chaperones, normally found in CSF, on these processes. We show that the
Alzheimer's disease CSF samples tested were more toxic to cultured neuroblastoma cells than normal
CSF. In addition, the Alzheimer's disease CSF samples tested were less able to protect cells from A betainduced toxicity and less efficient at promoting macrophage-like cell uptake when compared to normal
CSF. The addition of physiologically relevant concentrations of the extracellular chaperones, clusterin,
haptoglobin and alpha(2)-macroglobulin into CSF protected neuroblastoma cells from II1-422 toxicity and
promoted II1-422 uptake in macrophage-like cells. These results suggest that extracellular chaperones
are an important element of a system of extracellular protein folding quality control that protects against
A beta toxicity and accumulation.
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Abstract Alzheimer’s disease is characterised by the
inappropriate death of brain cells and accumulation of the
Aβ peptide in the brain. Thus, it is possible that there are
fundamental differences between Alzheimer’s disease
patients and healthy individuals in their abilities to clear
Aβ from brain fluid and to protect neurons from Aβ
toxicity. In the present study, we examined (1) the
cytotoxicity of Alzheimer’s disease cerebrospinal fluid
(CSF) compared to control CSF, (2) the ability of
Alzheimer’s disease and control CSF to protect cells from
Aβ toxicity and to promote cell-mediated clearance of Aβ
and lastly (3) the effects of extracellular chaperones,
normally found in CSF, on these processes. We show that
the Alzheimer’s disease CSF samples tested were more
toxic to cultured neuroblastoma cells than normal CSF. In
addition, the Alzheimer’s disease CSF samples tested were
less able to protect cells from Aβ-induced toxicity and less
efficient at promoting macrophage-like cell uptake when
compared to normal CSF. The addition of physiologically
relevant concentrations of the extracellular chaperones,
clusterin, haptoglobin and α2-macroglobulin into CSF
protected neuroblastoma cells from Αβ1-42 toxicity and
promoted Αβ1-42 uptake in macrophage-like cells. These
results suggest that extracellular chaperones are an impor-
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tant element of a system of extracellular protein folding
quality control that protects against Aβ toxicity and
accumulation.
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Abbreviations
ECs Extracellular chaperones
BSA Bovine serum albumin
LRP Low density lipoprotein receptor related protein
α2m α2-macroglobulin
Hp
Haptoglobin
Aβ
Amyloid beta peptide
QC
Quality control
CSF Cerebrospinal fluid
ALS Amyotrophic lateral sclerosis

Introduction
Aβ is the major constituent in extracellular plaques
characteristic of Alzheimer’s disease and its increased
expression is thought to be the triggering event leading to
disease pathology (Silvestrelli et al. 2006). This is
supported by the fact that, in all cases of early-onset
familial Alzheimer’s disease where a genetic mutation has
been identified, the defective gene causes an increase in
production of the more toxic processing variant Aβ1–42
(Mattson 2004; Iwata et al. 2005). The actual mechanism
by which Aβ is toxic is unclear; there are several
hypotheses. Aβ aggregates, such as mature fibrils (Mattson
2004) and soluble oligomers (Klein 2002), are toxic to cells
in vitro and are thought to cause pathology in humans
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(Gong et al. 2003). Aβ has also been linked to other toxic
pathways involving metal ions (e.g. Fe2+ and Cu2+) and
their subsequent generation of free radicals (Maynard et al.
2005). Aβ is also thought to trigger an inflammatory
response in the brain that may underpin disease pathology
(Silvestrelli et al. 2006) and be involved in cerebral
vascular dysfunction (Greenberg et al. 1996). Regardless
of the route of toxicity, it seems that even small increases in
soluble Aβ1–42 (even as small as a 1.5-fold increase) can
result in the appearance of aggressive presenile Aβ
pathology (Iwata et al. 2005).
Alzheimer’s disease is included in a group of disorders
that are associated with inappropriate protein deposits,
collectively known as protein deposition disorders. These
include Parkinson’s disease, amyotrophic lateral sclerosis
and Huntington’s disease which are associated with
deposits of α-synuclein, Cu/Zn superoxide dismutase and
huntingtin, respectively. It has been postulated that protein
deposits arise when the normally efficient protein folding
quality control system is overwhelmed (Muchowski and
Wacker 2005; Wilson et al. 2008). However, once in the
extracellular space, Aβ is no longer under the surveillance
of the intracellular protein folding quality control (QC)
system. Recently, it was proposed that an analogous
extracellular protein folding QC system exists that recognises non-native proteins and promotes their removal from
the extracellular fluid via receptor-mediated endocytosis
(Yerbury et al. 2005a, b). It has been shown that clusterin,
a ubiquitous and highly conserved secreted protein found
in human blood, is a potent extracellular chaperone
(Humphreys et al. 1999; Poon et al. 2000; Poon et al.
2002). More recently, both haptoglobin (Hp; previously
best known for its high affinity binding to haemoglobin;
Yerbury et al. 2005a,b) and α2-macroglobulin (α2m;
previously best known as an inhibitor of many proteases;
French et al. 2008) have been shown to possess potent
chaperone actions similar to clusterin. All three of these
known extracellular chaperones can be detected colocalised with “plaques” in Alzheimer’s disease (Powers
et al. 1981; Strauss et al. 1992; Kida et al. 1995). The
reason for their presence there is unknown but it is likely
that their chaperone action has been overwhelmed and that
they have consequently been co-deposited with Aβ
(Yerbury et al. 2007). In addition, clusterin, Hp and α2m
have already been shown to inhibit amyloid fibril formation
by Aβ in vitro (Hughes et al. 1998; Yerbury et al. 2007;
2009). Clusterin and α2m have previously been shown to
complex with Aβ in vitro and facilitate its transport via
receptor-mediated endocytosis to lysosomes for degradation
(Hammad et al. 1997; Narita et al. 1997). This is consistent
with in vivo studies in mice which show that α2m and
clusterin increase the rate of Aβ removal from the brain
(Shibata et al. 2000) (Bell et al. 2007).
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Since it has been proposed that Aβ metabolism in the
brain is dysfunctional in Alzheimer’s disease (Iwata et al.
2005), we wondered whether there was a fundamental
difference between Alzheimer’s disease patients and
healthy individuals in their ability to promote cellular
uptake/removal of Aβ from CSF or to protect neurons
from Aβ toxicity. Previous work has shown that normal
human CSF inhibits the formation of Aβ amyloid fibrils in
vitro while Alzheimer’s disease patient CSF does not (Ono
et al. 2005). In addition, previous studies have shown that
CSF from patients suffering other neurodegenerative
diseases such as ALS (Couratier et al. 1994) or Parkinson’s
(Le et al. 1999) is itself toxic to neuronal cells in vitro. In
the present study, we examined the toxicity of Alzheimer’s
disease CSF compared to control CSF. In addition, we
examined the ability of Alzheimer’s disease and control
CSF, with or without added extracellular chaperones, to
protect cells from Aβ toxicity and to promote cell-mediated
clearance of Aβ.

Results
Alzheimer’s CSF is toxic to SY5Y cells
CSF from patients with the neurodegenerative diseases
ALS and Parkinson’s disease is toxic to cells in vitro
(Couratier et al. 1994; Le et al. 1999). To determine
whether Alzheimer’s disease CSF is cytotoxic, SH-SY5Y
neuroblastoma cells were incubated in Aim V (Invitrogen,
Sydney, Australia) supplemented with a range of levels of
human normal and Alzheimer’s CSF for 48 h (e.g. a
mixture of equal volumes of Aim V and CSF is referred to
as 50% CSF). All samples were analysed individually and
then the results were averaged. All CSF samples were
collected and supplied by the National Neural Tissue
Resource Centre (Melbourne, Australia); individual donors
were confirmed as Alzheimer’s or non-Alzheimer’s by post
mortem examination of brain sections. Alzheimer’s CSF
was obtained from three males aged 68, 71 and 82
(designated AD 1, 2 and 3, respectively, in Figs. 2 and 4),
while non-Alzheimer’s CSF was obtained from three males
aged 48, 51 and 69 (designated Normal 1, 2 and 3,
respectively, in Figs. 2 and 4). CSF from non-symptomatic
donor tissue that contained Aβ plaques were excluded from
the “Normal” control samples—this had the consequence
that exactly age-matched controls were unavailable. Following incubation with CSF, cells were assayed for
viability using calcein-AM (Lichtenfels et al. 1994). The
calcein fluorescence of cells incubated with 50% (v/v)
normal control CSF was not significantly different to cells
incubated without added CSF (Fig. 1, Student's t test, p>
0.05), indicating that under the conditions tested normal
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extracellular chaperone levels prompted us to test whether
adding exogenous extracellular chaperones into Alzheimer’s CSF would protect cells from its toxicity.
Compared to cells incubated with Alzheimer’s CSF alone,
those incubated with Alzheimer’s CSF supplemented with
2 μg/ml clusterin, 2 μg/ml haptoglobin and 4 μg/ml α2m
showed significantly greater viability after 48 h (Fig. 2c;
p<0.05). In contrast, when the same concentrations of
extracellular chaperones were added to normal CSF, this
had no effect on the resulting cell viability (Fig. 2c).

Fig. 1 AD CSF is toxic to SH-SY5Y cells. Loss of viability of SHSY5Y cells, measured as calcein fluorescence and expressed as
percentage of untreated control cultures. Cells were cultured for 48 h
in FBS-free AIM V medium, with or without various levels of CSF.
The % CSF on the x-axis corresponds to the amount of CSF present
(v/v) in the media. Calcein-AM was used to measure cell viability.
Calcein-AM (1 μM) was added to cells and left to incubate for 30 min
before analysing fluorescence using a FLUOstar OPTIMA plate reader
with excitation and emission windows of 485±10 nm and 520±
10 nm, respectively. Significant differences (p<0.05) from the no
additives control are indicated by *. The data points shown represent
means of all samples from three independent experiments, with 12
samples in total, the error bars are SE

Alzheimer’s CSF promotes Aβ1-42 toxicity which
is modulated by extracellular chaperones
Aβ1-42 was incubated under amyloid forming conditions, as
previously reported (Yerbury et al. 2007), and samples
removed at 2 h. When incubated with cells in the absence

CSF was not toxic to SH-SY5Y cells. In contrast, the
calcein fluorescence of cells incubated with 50% Alzheimer’s CSF was significantly less. The toxicity of
Alzheimer’s CSF was dose dependent—the level of calcein
fluorescence decreased with increasing concentrations of
CSF (Fig. 1). The differences between control and
Alzheimer’s CSF treated wells were statistically significant
at both 25% and 50% (v/v) CSF (Student's t test, p<0.05).
Fluorescence microscopy of calcein-AM stained cells
confirmed that there were less viable cells and loss of
neurite outgrowth in wells containing 25% and 50%
Alzheimer’s CSF compared to those incubated with control
CSF (data not shown).
Addition of extracellular chaperones protects cells
from Alzheimer’s CSF toxicity
Immunoblotting analysis of the CSF samples used in this
study showed that the levels of all three extracellular
chaperones tested (α2m, haptoglobin and clusterin) were
higher in control CSF than in Alzheimer’s CSF (Fig. 2a). In
addition, a BCA assay indicated that the total protein
concentrations in the Alzheimer’s CSF samples used in this
study were on average lower than that of normal CSF
(Fig. 2b). Thus, the difference in extracellular chaperone
levels may be due to differences in total protein concentration between control and Alzheimer’s CSF, rather than a
selective depletion of extracellular chaperones in Alzheimer’s CSF (Fig. 2a, b). Regardless, the differences in

Fig. 2 Extracellular chaperones protect SH-SY5Y cells from AD CSF
toxicity. a Western blot images showing levels of α2m, Hp and
clusterin in 5 μl of CSF. b Protein concentration in CSF samples
measured using BCA assay. BSA was used to create a standard curve
and the assay was conducted as per the manufacturer’s instructions.
For (a) and (b), individual CSF samples are labelled 1–3 (see first
paragraph in Results section). c Loss of viability of SH-SY5Y cells,
measured as calcein fluorescence and expressed as percentage of
untreated control cultures. Cells were cultured for 48 h in FBS-free
AIM V medium, with or without individual CSF samples and/or a
cocktail of 2 μg/ml clusterin, 2 μg/ml haptoglobin and 4 μg/ml α2m.
1 μM Calcein-AM was used to measure cell viability. Significant
differences (p<0.05) from the control CSF sample are indicated by *.
The data points shown represent means of all samples from three
independent experiments, with nine samples in total, the error bars
are SE
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cells incubated with 50% Alzheimer’s CSF, a significant
loss of viability resulted (Fig. 3, Alzheimer’s CSF+Aβ
versus N CSF+Aβ; Student’s t test, p<0.05). Addition of
extracellular chaperones to cells incubated with Aβ
supplemented Alzheimer’s CSF provided significant protection (Student’s t test, p<0.05). However, the protection
provided by extracellular chaperones did not bring cell
viability back to the level of controls (Fig. 3 Alzheimer’s
CSF+Aβ+extracellular chaperone versus N CSF+Aβ;
Student’s t test, p<0.05).
Extracellular chaperones promote macrophage-mediated
uptake of Aβ1-42 from CSF

Fig. 3 Normal CSF and extracellular chaperones protect SH-SY5Y
cells from Aβ1-42 toxicity. Loss of viability of SH-SY5Y cells,
measured as calcein fluorescence and expressed as percentage of
untreated control cultures, incubated for 48 h with Aβ1-42 alone or in
the presence of CSF with or without added extracellular chaperones
(2 μg/ml clusterin, 2 μg/ml haptoglobin and 4 μg/ml α2m). To induce
cytotoxicity, aliquots of Aβ1-42 reactions (taken at 2 h) were added to
cells alone to give final concentrations of 1 μM. Aggregation of Aβ1-42
(10 μM) was initiated by incubation in PBS containing 90 mM CaCl2,
50 mM MgCl2, 100 mM CuCl2, 600 mM glycine, pH 7.5. Significant
differences from the normal CSF alone sample are indicated by *.
Significant differences from the AD CSF+Aβ sample are indicated by #.
The data points shown represent means of all samples from three
independent experiments, with nine samples in total, the error bars are SE

of CSF, these prefibrillar fractions were toxic to SH-SY5Y
cells in a dose-dependent manner (Yerbury et al. 2007). The
possibility that CSF could protect cells from toxic Aβ1-42
species was examined. When toxic Aβ1-42 aggregates were
added to cells incubated in 50% (v/v) normal CSF, there
was no significant loss of viability (Fig. 3). In contrast,
when the same dose of Aβ1-42 aggregates were added to

Fig. 4 AD CSF inhibits Aβ1-42 uptake by macrophage-like cells.
Western blot image of Aβ1-42 remaining in the CSF containing
supernatant after incubation with PMA-differentiated macrophage-like
U937 cells. Exogenous Aβ1-42 was added to CSF to give a
concentration of 1 μM. The CSF was diluted 1:1 in AIM V and
added to cells and incubated for 24 h. At the conclusion of the
incubation, samples were centrifuged for 10 min at 3,000×g. The
supernatant was removed and analysed by 15% SDS PAGE and

Since the metabolism of Aβ1-42 in the brain is thought to be
defective (Iwata et al. 2005), we examined the possibility
that Alzheimer’s CSF negatively affected the uptake of
Aβ 1-42 by macrophages. Aβ was added to PMAdifferentiated macrophage-like U937 cells incubated with
either Alzheimer’s or normal CSF (50%) and after 24 h the
supernatant was collected and analysed by immunoblotting.
In all cases, the supernatant from cells incubated with
Alzheimer’s CSF contained more Aβ1-42 than supernatant
from cells incubated with normal CSF (Fig. 4). In two of
three cases, there was no remaining Aβ detected in culture
supernatants of cells incubated with normal CSF samples
(Fig. 4). A large fraction of the Aβ1-42 present in supernatants
from cultures incubated with Alzheimer’s CSF was present
as SDS-resistant oligomers. The oligomers ranged from
around 10 kDa to just under 25 kDa, corresponding to two to
five Aβ monomers (one monomer ~4.5 kDa) (Fig. 4). When
compared with corresponding non-extracellular chaperonesupplemented cultures, the addition of extracellular chaperones decreased the amount of Aβ1-42 remaining in the
supernatant (Fig. 4). Furthermore, for the Alzheimer’s CSF
supplemented cultures, the addition of extracellular chaper-

subsequent immunoblotting using WO2 (anti-Aβ monoclonal antibody). Bound specific antibodies were detected with HRP-conjugated
sheep anti-mouse Ig antibody followed by enhanced chemiluminescence (ECL) with Supersignal West Pico Chemiluminescent Substrate.
Individual CSF samples are labelled 1–3 (see first paragraph in
Results section). Results shown are representative of at least two
independent experiments
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ones reduced the fraction of supernatant Aβ found in SDSresistant oligomers (Fig. 4).

the current study, this may relate to the differences found in
the levels of the extracellular chaperones clusterin, α2m and
Hp. The lower total protein concentration of Alzheimer’s
CSF may account for the lower concentrations of extracellular chaperones in Alzheimer’s CSF found in this study,
suggesting that extracellular chaperones are not selectively
depleted from this fluid. This is consistent with previous
work showing that Alzheimer’s disease patient CSF has a
lower total protein concentration than normal CSF controls
(Morihara et al. 1998). In contrast, previous studies
suggested that the concentration of at least one of the
extracellular chaperones, clusterin, is not lower in Alzheimer’s CSF (Lidstrom et al. 2001; Nilselid et al. 2006).
However, while previous studies suggest that clusterin
concentration does not differ in spinal fluid of Alzheimer’s
patients, it is possible that the differences in relative
clusterin levels in spinal fluid described in the current
study could be attributed to technical differences between
the Western blotting technique used here and the ELISA
method used previously (Lidstrom et al. 2001; Nilselid et
al. 2006). It is also impossible to rule out the possibility that
the differences seen in the present study could be due to the
small sample size used.
In the current study using Western blotting, we show that
the levels of clusterin, α2m and Hp are lower in samples of
Alzheimer’s CSF compared to normal CSF. Moreover,
addition of exogenous extracellular chaperones into Alzheimer’s CSF provided partial protection to neuroblastoma
cells from Aβ toxicity. Previous studies have also shown
that clusterin and α2M protect cells in primary rat mixed
neuronal cultures from Aβ toxicity (Boggs et al. 1996; Du
et al. 1997). Taken together, these results are consistent
with the idea that, in the CSF of Alzheimer's patients, lower
levels of extracellular chaperones may render the CSF less
able to sequester and safely remove Aβ than is the case in
healthy individuals. Both α2m and clusterin have been
shown to mediate cellular Aβ uptake via receptor-mediated
endocytosis (Hammad et al. 1997; Narita et al. 1997). This
is in accordance with the theory that these extracellular
chaperones play a role in sequestering and disposing of
dangerously hydrophobic proteins or peptides in vivo
(Yerbury et al. 2005a,b; Wilson et al. 2008). The current
study suggests that Alzheimer’s CSF is less effective at
promoting the cellular uptake of exogenously added Aβ
than control CSF and that the addition of extracellular
chaperones can promote the uptake of Aβ 1-42 by
macrophage-like cells. This is consistent with in vivo
studies that show that the rate of clearance of Aβ from
the mouse brain is significantly increased by both α2m
(Shibata et al. 2000) and clusterin (Bell et al. 2007).
In conclusion, the results presented here are consistent
with a model in which extracellular chaperones bind Aβ
and maintain its solubility, protect cells from its toxicity and

Discussion
It is thought that an increase in Aβ production and/or a
reduced rate of clearance of Aβ from extracellular central
nervous system fluids may be contributing factors in the
development of Alzheimer’s pathology (Iwata et al. 2005).
One or more types of soluble Aβ species are likely to be
responsible for the neurotoxicity associated with Alzheimer’s disease, as the pathology is correlated with
elevated levels of Aβ in the brain (Naslund et al. 2000)
but does not correlate well with the location of insoluble
Aβ plaques (Terry et al. 1991). In the current study, we
have shown that Alzheimer’s CSF is toxic when incubated
with neuroblastoma cells of human origin (SH-SY5Y)
(Fig. 1). The toxicity can, at least in part, be suppressed
by the addition of extracellular chaperones at concentrations equivalent to those found in normal human CSF. The
extracellular chaperones clusterin, haptoglobin and α2m are
present in normal human CSF at 2 μg/ml, 0.5–2 μg/ml and
1–3.6 μg/ml, respectively (Murphy et al. 1988; Sobek and
Adam 2003; Biringer et al. 2006). The mechanism by
which Alzheimer’s CSF is toxic and the means by which
extracellular chaperones protect cells from Alzheimer’s
CSF cytotoxicity is unknown. Extracellular chaperones,
such as clusterin, have been shown to protect cells from a
range of stresses (Wilson and Easterbrook-Smith 2000).
Clusterin and α2m have both been shown to protect cells
from Aβ toxicity (Boggs et al. 1996; Fabrizi et al. 2001)
and TNFα-mediated cell death (Humphreys et al. 1997;
Arandjelovic et al. 2007). α2m can also protect cells by
binding to and trapping proteases (Ikari et al. 2001). It has
been demonstrated that both clusterin and Hp protect cells
from oxidative stress-induced toxicity (Schwochau et al.
1998; Melamed-Frank et al. 2001). It is possible that one or
more of these potential mechanisms of toxicity are being
blocked by the action of the extracellular chaperones.
Collectively, this suggests that these extracellular chaperones may play a cytoprotective role in Alzheimer’s disease.
We next examined the ability of CSF to protect
neuroblastoma cells from the toxicity of added exogenous
Aβ1-42. Under the conditions tested, normal CSF protected
cells from Aβ1-42 toxicity, while Alzheimer’s CSF did not
(Fig. 3). This is consistent with the fact that the in vitro
formation of amyloid fibrils by Aβ is inhibited by normal
human CSF but less so by Alzheimer’s CSF (Ono et al.
2005). Taken together, these results suggest that, at least in
the samples tested, there is a fundamental change in the
composition of Alzheimer’s CSF that compromises its
ability to inhibit the aggregation and toxicity of Aβ. In
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subsequently promote its removal from the brain fluid via
receptor-mediated endocytosis. Results from this study
suggest that Alzheimer’s CSF is less able to protect cells
from Aβ toxicity and promote removal of Aβ from CSF. In
addition, our results suggest that increasing the concentration of extracellular chaperones in Alzheimer’s brain fluid
may alleviate Aβ toxicity and promote its removal from the
brain. Thus, increasing the concentration of extracellular
chaperones in the brain may represent a potential therapeutic strategy for the treatment of Alzheimer’s disease.
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